Full-Time

Market Access & Pricing Lead

International

Updated on 9/13/2026

Deadline 9/19/26
Pfizer

Pfizer

10,001+ employees

Biopharmaceutical company develops medicines and vaccines

Compensation Overview

$214.9k - $358.1k/yr

+ 22.5% bonus target + Share-based long-term incentive

No H1B Sponsorship

Paris, France + 1 more

More locations: New York, NY, USA

Hybrid

Hybrid work arrangement; relocation assistance may be available based on business needs and eligibility.

Bachelor's, Master's, PhD

Category
Business & Strategy (1)
Required Skills
Data Analysis

Get referred to Pfizer

See people who can refer or advise you

Requirements
  • A Bachelor's degree with at least 12+ years of experience, or a Master's degree with more than 10+ years of experience, or a Ph.D. with 7+ years of experience.
  • Progressive experience in pricing, market access, or commercial strategy within pharmaceuticals, biosimilars, or generics.
  • Deep expertise in international pricing frameworks, reference pricing systems, cross-border pricing risk management, and tender-driven market dynamics.
  • Proven experience in above-market or regional pricing and access roles with demonstrated influence on portfolio P&L outcomes.
  • Strong understanding of international reference pricing dynamics and cross-border pricing risk management.
  • Strong analytical capabilities, including modeling pricing scenarios, assessing cross-border implications, and translating complex analytics into clear strategic recommendations.
  • Experience shaping payor and institutional access strategies across multiple geographies.
  • Fluency in English.
Responsibilities
  • Define the international pricing framework for the GH&B portfolio, including pricing corridors, floor and ceiling thresholds, reference pricing principles, and market-type archetypes.
  • Own pricing governance by setting decision rights, escalation criteria, and approval thresholds for market-level pricing actions with material P&L impact.
  • Lead pricing strategy for new product launches, competitive responses, and tender rebids.
  • Ensure pricing compliance across markets through structured oversight and exception management, identifying cross-border reference pricing risks and recommending corrective actions.
  • Set the above-market access and reimbursement strategy for the GH&B portfolio, including formulary positioning, health technology assessment engagement principles, and institutional access pathways.
  • Provide strategic guidance to clusters on reimbursement negotiations, hospital listing strategies, and payor value propositions.
  • Develop access playbooks and value argumentation frameworks for local market teams.
  • Monitor the policy and regulatory landscape and advise on implications for portfolio access and pricing strategy.
  • Define the pricing and access performance agenda, including key performance indicators and commercial performance infrastructure requirements.
  • Partner with the Director of Business Operations and Commercial Performance function to embed pricing and access analytics in the commercial performance infrastructure.
  • Define mitigation scenarios for revenue-at-risk scenarios in partnership with the Biosimilars and Hospital Portfolio Leads.
  • Serve as strategic advisor to Cluster Leads and local Tender, Contracting, and Account Management teams on pricing and access decisions.
  • Build pricing and market access as a discipline across the international community by developing tools, training, and decision frameworks.
  • Enable dissemination of winning approaches across clusters through structured peer-learning channels.
  • Influence commercial decision-making across clusters by building trust and demonstrating value.
  • Integrate pricing and access strategy with portfolio strategy, supply realities, and financial planning.
  • Define pricing corridors and escalation triggers, intervening on out-of-corridor decisions.
  • Partner with the Partnerships & Alliances Lead on pricing dimensions of external partnerships, distribution agreements, and alliance structures.
  • Coordinate with Regulatory and Medical on access-related submissions, clinical evidence requirements, and policy advocacy.
  • Align with Pfizer Global Pricing and Market Access functions on enterprise pricing policies, transfer pricing, and cross-business-unit reference pricing exposure.
  • Define requirements for pricing and access tooling, including competitive price monitoring, scenario modeling, and corridor compliance dashboards.
  • Demonstrate practical use of data, digital tools, and artificial intelligence-enabled solutions.
  • Model artificial intelligence-enabled ways of working within the pricing and access discipline.
  • Champion adoption of artificial intelligence-enabled pricing analytics, including tender outcome prediction, price elasticity modeling, and reference pricing simulation.
  • Ensure responsible use of artificial intelligence in pricing decisions through appropriate governance and human oversight.
  • Lead leaders and teams through complex change while navigating ambiguity, influencing stakeholders, and sustaining performance during transformation.
  • Connect strategy to execution across functions and anticipate downstream impacts to deliver integrated, enterprise-level solutions.
  • Make high-stakes pricing decisions in competitive, margin-sensitive environments where speed and accuracy both matter.
Desired Qualifications
  • Additional languages.
  • A Master's degree with relevant pharmaceutical industry experience.
  • Direct experience in biosimilar or generics pricing and market access, including tender strategy and competitive price positioning.
  • Background in health economics, health technology assessment submissions, or institutional formulary management.
  • Experience designing pricing governance frameworks and escalation processes for multi-market organizations.
  • A track record of building pricing and access capabilities across dispersed teams.
  • Experience working within integrated end-to-end business models where cost-to-serve directly shapes pricing strategy.
  • Proficiency in pricing analytics tools and business intelligence platforms.

Pfizer is a global biopharmaceutical company that discovers, develops, manufactures, and sells medicines and vaccines for a range of health needs, including vaccines, oncology, and other specialized therapies. Its products work by using biological mechanisms to prevent or treat diseases—vaccines train the immune system to fight infections, while medicines target cancer and other conditions. Pfizer differentiates itself through its large worldwide footprint, broad portfolio across multiple therapeutic areas, and partnerships (notably with BioNTech) that expanded its reach in vaccines and cutting-edge therapies. The company also engages in public health initiatives, such as efforts to provide vaccines to underserved populations. Pfizer’s broad goal is to improve global health by delivering safe and effective medicines and vaccines through research, development, and wide international distribution.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1849

Get referred to Pfizer

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue rose to $15 billion, and non-COVID products grew 5% operationally.
  • Pfizer raised 2026 guidance to $60.5 billion-$62.5 billion after Eliquis, Padcev, Vyndaqel strength.
  • Berobenatide entered Phase 3 planning, giving Pfizer a credible obesity franchise before 2028.

What critics are saying

  • Depo-Provera MDL exceeded 5,800 cases by July 2026, with late-2026 bellwethers looming.
  • Vyndamax still faces Apotex litigation in Delaware, preserving generic-entry uncertainty beyond 2031.
  • Ringaskiddy and Catania cuts show manufacturing contraction, signaling more restructuring through 2029.

What makes Pfizer unique

  • Seagen gives Pfizer leading ADCs: Padcev, Tivdak, Adcetris, Tucysa across oncology.
  • Pfizer still owns COMIRNATY distribution scale, with XFG vaccine approved August 27, 2026.
  • Vyndamax settlement extends U.S. exclusivity to June 1, 2031, stabilizing cardiomyopathy cash flows.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Hybrid Work Options

Relocation Assistance

Growth & Insights and Company News

Headcount

6 month growth

-5%

1 year growth

-5%

2 year growth

-5%
Yahoo Finance
Sep 10th, 2026
Medicus Pharma secures Pfizer ADC deal with $2M funding, advances SkinJect for rare cancer treatment

Medicus Pharma has secured a development and licensing agreement with Pfizer for a CD228-targeted antibody-drug conjugate programme focused on solid tumours, including refractory melanoma. Pfizer is providing approximately $2 million in development funding, plus inventory and infrastructure support. CEO Dr Raza Bokhari said the deal allows Medicus to continue from where Pfizer concluded its Phase 1 dose-escalation work, strengthening the company's position in precision oncology. Medicus is also advancing its SkinJect programme for basal cell carcinoma. Final clinical trial results identified the 200-microgram patch as the optimal dose for future studies. The company is preparing for the FDA-approved pivotal SkinJect 005 study whilst recruiting patients. An independent reimbursement analysis suggests SkinJect could achieve reimbursement levels of $25,000 or more per patient.

Yahoo Finance
Sep 8th, 2026
AbbVie beats Pfizer as top dividend stock with 53-year payout streak and 203% growth

AbbVie offers a smarter long-term dividend investment than Pfizer, despite Pfizer's higher 6.1% yield. AbbVie holds Dividend King status with 53 consecutive years of dividend increases and raised its payout by 5.5% this year to $1.73 per share. Over the past decade, AbbVie increased its dividend by more than 203% compared to Pfizer's 51%. AbbVie's revenue grew 138% during this period, whilst Pfizer's rose just 18%. AbbVie successfully navigated Humira's patent cliff through home-grown immunology drugs Skyrizi and Rinvoq. By 2025, these two drugs generated combined annual sales exceeding $25 billion, replacing Humira's peak revenue and pushing total company revenue to record highs. AbbVie's free-cash-flow dividend payout ratio stands at 65%, lower than Pfizer's 89%.

Yahoo Finance
Aug 28th, 2026
Pfizer's updated COVID vaccine ships as FDA approves narrower rollout for over-65s and high-risk groups

Pfizer received FDA approval for its updated Comirnaty COVID-19 vaccine on Thursday, with deliveries to pharmacies and clinics beginning immediately. The company's shares were trading at $27.9079 on 28 August. However, the market opportunity has significantly narrowed from pandemic levels. Eligibility is now limited to adults aged 65 and older, plus higher-risk patients aged 5 through 64. Despite Comirnaty having distributed over five billion doses worldwide historically, today's revenue potential is considerably more constrained. Pfizer faces competition from Moderna and the Novavax-Sanofi protein vaccine for this smaller patient pool. The company's current share price sits 5.27% above its estimated value of $26.51, suggesting investors are paying a premium before actual uptake and commercial results become clear.

Associated Press
Aug 27th, 2026
FDA approves Pfizer-BioNTech XFG-adapted COVID-19 vaccine for high-risk groups

Pfizer and BioNTech have received US Food and Drug Administration (FDA) approval for their 2026-2027 COVID-19 vaccine targeting the XFG variant. The vaccine is approved for adults aged 65 and older, and individuals aged 5 to 64 with underlying conditions that increase risk of severe COVID-19 outcomes. The FDA approval is based on clinical, non-clinical and real-world data demonstrating the vaccine generates strong immune responses against currently circulating SARS-CoV-2 variants, including XFG and other contemporary lineages. The XFG variant was selected following FDA guidance for fall 2026 vaccine composition. The vaccine will begin shipping immediately and will be available in US pharmacies, hospitals and clinics within days. To date, more than five billion doses of COMIRNATY have been distributed globally.

Yahoo Finance
Aug 24th, 2026
Pfizer and J&J navigate patent cliffs with newer drugs offsetting blockbuster losses

Pfizer and Johnson & Johnson are navigating patent cliffs as key drugs lose exclusivity, with their latest results showing differing stages of transition. Pfizer's revenue excluding COVID products grew 5% operationally in Q2 2026, with newer medicines like Padcev and Vyndaqel contributing. The company expects $9.7 billion in cost savings through 2029 to support margins during the transition. Johnson & Johnson's Innovative Medicine sales rose 7.8%, despite Stelara revenue declining 55%. Tremfya sales surged 72.5% to $2 billion, helping offset losses alongside growth from oncology and neuroscience products. Johnson & Johnson raised 2026 guidance, with reported sales expected to reach $101.1 billion and adjusted EPS of $11.68. Its MedTech division provides additional diversification that pure pharmaceutical company Pfizer lacks, suggesting Johnson & Johnson's transition is more advanced.